Across TCGA pan-cancer cohorts, CRYGS mass-spec protein is linked to patient survival in 1 of 34 cancer types, making it a survival-associated CRYGS data layer compared with 23 for mass-spec protein and 3 for mutation status.
The strongest signal is observed in glioblastoma multiforme (GBM), where higher CRYGS mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated CRYGS expression acts as an unfavorable survival marker.
GBM are the cancer types where CRYGS mass-spec protein most reproducibly stratifies survival.